Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation.

Mhawech P, Benz A, Cerato C, Greloz V, Assaly M, Desmond JC, Koeffler HP, Lodygin D, Hermeking H, Herrmann F, Schwaller J.

Mod Pathol. 2005 Mar;18(3):340-8.

2.

The role of epigenetic inactivation of 14-3-3sigma in human cancer.

Lodygin D, Hermeking H.

Cell Res. 2005 Apr;15(4):237-46. Review.

3.

Epigenetic silencing of 14-3-3sigma in cancer.

Lodygin D, Hermeking H.

Semin Cancer Biol. 2006 Jun;16(3):214-24. Epub 2006 Apr 1. Review.

PMID:
16698281
4.

14-3-3 proteins--an update.

Mhawech P.

Cell Res. 2005 Apr;15(4):228-36. Review.

5.

GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.

Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG.

J Cell Biochem. 2004 Feb 15;91(3):540-52. Review.

PMID:
14755684
6.

Epigenetic gene silencing in cancer initiation and progression.

Nephew KP, Huang TH.

Cancer Lett. 2003 Feb 20;190(2):125-33. Review.

PMID:
12565166
7.

Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers.

Horie-Inoue K, Inoue S.

Semin Cancer Biol. 2006 Jun;16(3):235-9. Epub 2006 Apr 1. Review.

PMID:
16682214
8.

Beyond the island: epigenetic biomarkers of colorectal and prostate cancer.

Savio AJ, Bapat B.

Methods Mol Biol. 2015;1238:103-24. doi: 10.1007/978-1-4939-1804-1_6. Review.

PMID:
25421657
9.

Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers.

Risinger JI, Maxwell GL, Berchuck A, Barrett JC.

Ann N Y Acad Sci. 2003 Mar;983:208-12. Review.

PMID:
12724225
10.

Epigenetics in ovarian cancer.

Seeber LM, van Diest PJ.

Methods Mol Biol. 2012;863:253-69. doi: 10.1007/978-1-61779-612-8_15. Review.

PMID:
22359298
11.

Role of epigenomics in ovarian and endometrial cancers.

Balch C, Matei DE, Huang TH, Nephew KP.

Epigenomics. 2010 Jun;2(3):419-47. doi: 10.2217/epi.10.19. Review. Erratum in: Epigenomics. 2011 Apr;3(2):246.

12.

[GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer].

Bastian PJ, Nakayama M, De Marzo AM, Nelson WG.

Urologe A. 2004 May;43(5):573-9. Review. German.

PMID:
15029477
13.

Epigenetic gene deregulation in cancer.

Malik K, Brown KW.

Br J Cancer. 2000 Dec;83(12):1583-8. Review.

14.

The role of tissue microdissection in cancer research.

Gillespie JW, Ahram M, Best CJ, Swalwell JI, Krizman DB, Petricoin EF, Liotta LA, Emmert-Buck MR.

Cancer J. 2001 Jan-Feb;7(1):32-9. Review.

PMID:
11269646
15.

Cancer genetics.

Ponder BA.

Nature. 2001 May 17;411(6835):336-41. Review.

PMID:
11357140
16.

Application of DNA methylation biomarkers for endometrial cancer management.

Jiang SW, Li J, Podratz K, Dowdy S.

Expert Rev Mol Diagn. 2008 Sep;8(5):607-16. doi: 10.1586/14737159.8.5.607. Review.

PMID:
18785809
17.

Aging, DNA methylation and cancer.

Issa JP.

Crit Rev Oncol Hematol. 1999 Sep;32(1):31-43. Review. No abstract available.

PMID:
10586353
18.

[Molecular diagnostics in oncology].

Imianitov EN.

Vopr Onkol. 2012;58(2):153-63. Review. Russian. No abstract available.

PMID:
22774518
19.

Significance of metallothionein overexpression in human tumours.

Jasani B, Schmid KW.

Histopathology. 1997 Sep;31(3):211-4. Review. No abstract available.

PMID:
9354889
20.

Fluorescence in situ hybridization analysis of biomarkers in cancer.

Mark HF.

Exp Mol Pathol. 1999 Dec;67(3):131-4. Review. No abstract available.

PMID:
10600395

Supplemental Content

Support Center